Stage IB Endometrial Cancer

Bottke, Dirk; Wiegel, Thomas; Kurzeder, Christian; Sauer, Georg

doi:10.1007/s00066-007-1801-3

Cited by 12 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The conductance of systematic LNE, especially in early stage EC, has been actively disputed over the past years [ 4 ]. Two randomized trials did not find a survival benefit from systematic pelvic LNE in EC [ 5 , 6 ].…”

Section: Discussionmentioning

confidence: 99%

Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist’s point of view

et al. 2015

View full text Add to dashboard Cite

BackgroundTo investigate the meaning of lymphadenectomy (LNE) in women with endometrial cancer (EC) for clinical outcome and secondly to determine the impact of the method of adjuvant radiotherapy (RT) on survival as well as to define prognostic factors.Methods322 patients (pts) underwent adjuvant RT for endometrioid EC at our department from 2004 until 2012 and were included in this retrospective study. Chi-square test, LogRank test and Cox regression were used for statistical analyses.ResultsMedian age at diagnosis: 66 years. FIGO stages: FIGO I 69.4 %, FIGO II 15.3 %, FIGO III 14.5 %, FIGO IV 0.9 %. Surgical staging: 30.6 % pelvic/paraaortic LNE, 45 % sole pelvic LNE, 8.8 % sampling of suspicious lymph nodes, 15.6 % no LNE. Adjuvant chemotherapy (ChT): 3.2 %. Sole intravaginal brachytherapy (IVB): 60.2 %. IVB + external beam radiotherapy (EBRT): 39.8 %. 5-year local recurrence free survival (LRFS): 90.6 %, distant metastases free survival (DMFS): 89.8 %, overall survival (OS):79.3 %. In multivariate analysis age (p = .007), pT stage (p = .029), lymph node status (p = .003), grading (p = .011) and lymphovascular space invasion (LVSI; p = .008) remained as independent prognostic factors for OS. Resection status (p = .01) and LVSI (p = .014) were independent prognostic factors for LRFS and LVSI (p = .008) was the only independent prognostic factor for DMFS. There was no statistically significant survival benefit from LNE in LRFS (p = .561), DMFS (p = .981) or OS (p = .791). 5-year LRFS in stage I and II: 96.0 and 82.9 % after sole IVB, 90.8 and 81.6 % after combined IVB/EBRT (p = .105; p = .970). 5-year OS rates for stage I and II: 86.5 and 71.3 % after sole IVB, 84.2 % and 69.2 % after combined IVB/EBRT (p = .153; p = .619).ConclusionComprehensive surgical staging is rarely performed and may be omitted in women with endometrioid EC in stages I-II. Sole IVB delivers equally good local control as combined IVB/EBRT in pts with FIGO stage I and II disease. LVSI deserves more attention as a prognostic factor and these pts may require a combined local and systemic therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist’s point of view

et al. 2015

View full text Add to dashboard Cite

show abstract

Imaging of Lymph Nodes

Barbieri

Härmä

Thoeny

2017

MRI and CT of the Female Pelvis

View full text Add to dashboard Cite

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

et al. 2011

View full text Add to dashboard Cite

Hormonal therapy and chemotherapy play a major role in the palliative management of patients with hematogenous metastases from endometrial carcinoma to the liver, lungs, and bones. Radical treatment in patients with metastases to the lung or liver consists of resection of the metastasis combined with chemo- and/or hormonotherapy for metastases to the bones treatment consists of radiotherapy + chemotherapy, for metastasis to the brain treatment consists of resection combined with radiotherapy.

show abstract

Stage IB Endometrial Cancer

Cited by 12 publications

References 37 publications

Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist’s point of view

Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist’s point of view

Imaging of Lymph Nodes

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

Contact Info

Product

Resources

About